Last reviewed · How we verify
Vayarin®, supplementation of n-3 PUFA
Vayarin®, supplementation of n-3 PUFA is a nutraceutical Small molecule drug developed by Hospices Civils de Lyon. It is currently in Phase 3 development for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
Vayarin® provides a targeted delivery of n-3 polyunsaturated fatty acids (PUFAs) to support brain health and function.
Vayarin® provides a targeted delivery of n-3 polyunsaturated fatty acids (PUFAs) to support brain health and function. Used for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents.
At a glance
| Generic name | Vayarin®, supplementation of n-3 PUFA |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Drug class | nutraceutical |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
The n-3 PUFAs in Vayarin®, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential for maintaining the integrity of neuronal membranes and modulating inflammation, which can improve cognitive function and behavior in individuals with certain neurological conditions.
Approved indications
- Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents
Common side effects
- Gastrointestinal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vayarin®, supplementation of n-3 PUFA CI brief — competitive landscape report
- Vayarin®, supplementation of n-3 PUFA updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Vayarin®, supplementation of n-3 PUFA
What is Vayarin®, supplementation of n-3 PUFA?
How does Vayarin®, supplementation of n-3 PUFA work?
What is Vayarin®, supplementation of n-3 PUFA used for?
Who makes Vayarin®, supplementation of n-3 PUFA?
What drug class is Vayarin®, supplementation of n-3 PUFA in?
What development phase is Vayarin®, supplementation of n-3 PUFA in?
What are the side effects of Vayarin®, supplementation of n-3 PUFA?
Related
- Drug class: All nutraceutical drugs
- Manufacturer: Hospices Civils de Lyon — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents
- Compare: Vayarin®, supplementation of n-3 PUFA vs similar drugs
- Pricing: Vayarin®, supplementation of n-3 PUFA cost, discount & access